v3.25.4
Shareholder Report
12 Months Ended
Nov. 30, 2025
USD ($)
Holdings
Shareholder Report [Line Items]  
Document Type N-CSR/A
Amendment Flag false
Registrant Name TANAKA Funds, Inc.
Entity Central Index Key 0001051219
Entity Investment Company Type N-1A
Document Period End Date Nov. 30, 2025
Class R  
Shareholder Report [Line Items]  
Fund Name TANAKA GROWTH FUND
Class Name Tanaka Growth Fund
Trading Symbol TGFRX
Annual or Semi-Annual Statement [Text Block]

This annual shareholder report contains important information about the Tanaka Growth Fund - TGFRX (the “Fund”) for the period December 1, 2024 to November 30, 2025.

 

Shareholder Report Annual or Semi-Annual annual shareholder report
Additional Information [Text Block]

You can find additional information about the fund at https://tanaka.com/tanaka-growth-fund. You can also request this information by contacting us at 1-877-4-TANAKA.

Additional Information Phone Number 1-877-4-TANAKA.
Additional Information Email https://tanaka.com/tanaka-growth-fund.
Expenses [Text Block]

What were the Fund costs for the past year?

(based on a hypothetical $10,000 investment)

 

Fund Name Costs of a $10,000 investment Costs paid as a percentage of a $10,000 investment*
     
Tanaka Growth Fund $231.00 1.95%

 

*Annualized

Expenses Paid, Amount $ 231.00
Expense Ratio, Percent 1.95%
Factors Affecting Performance [Text Block]

managment’s discussion of fund performance

 

The TANAKA Growth Fund gained 37.0% for its fiscal 2025 ending November 30th compared with gains of 16.8% for the Wilshire 2500 Growth index and 15.0% for the S&P 500. Mega Cap Tech and Artificial Intelligence continued to dominate market leadership during the year, and while the Fund benefited from holdings aligned with the AI infrastructure cycle, much of our outperformance was driven by small- and mid-cap stock picks in areas such as Health Care, Energy, Gold, and Critical Minerals. Performance was broad-based with three holdings up over 200%, eight up more than 40%, and ten up more than 20% during the fiscal year.

 

Two mid-cap Biotech stock picks were among the Fund’s top contributors, benefiting from strong commercial drug sales and positive clinical trial developments. Several metals and mining-related positions also contributed meaningfully to results, including a Gold producer that benefited from higher gold prices and the start-up of a new mine, Uranium holdings that gained amid rising demand for nuclear power, and a Critical Minerals company that secured large government and commercial contracts and is expanding its production capabilities. Our core Semiconductor and Semi Capital Equipment companies continued to play important roles in the AI infrastructure buildout while our Warehouse Automation holding remains a strong example of the productivity and cost efficiencies enabled by AI adoption. Partially offsetting these gains was a decline in an inverse S&P 500 ETF used as a market hedge, which we subsequently sold as markets recovered from the spring tariff-driven correction. In addition, one of our small-cap Biotech companies lagged following a clinical trial disruption, and our Consumer Staples and Financials positions underperformed the market as investor focus remained concentrated in Technology and AI.

 

As we enter the new year, our investment approach remains unchanged: focusing on companies with identifiable company-specific growth drivers that may be less dependent on broader market or macroeconomic conditions. We believe the continued growth of passive investing and increased market concentration are contributing to meaningful disconnects between stock prices and underlying fundamentals, particularly outside of Large Cap Technology. In our view, this environment creates a favorable backdrop for active investors like us to research and identify high-quality companies across sectors and market capitalizations that may be overlooked despite attractive long-term prospects.

Performance Past Does Not Indicate Future [Text] Past performance is not a good predictor of future performance
Line Graph [Table Text Block]

 

Line Graph Tanaka Wilshire 2500 Growth
11/30/2015 10000 10000
5/31/2016 8918 9783
11/30/2016 8927 10525
5/31/2017 9524 11909
11/30/2017 9852 13429
6/30/2018 9197 14387
11/30/2018 8517 14300
5/31/2019 7858 14627
11/30/2019 8700 17051
5/31/2020 8499 17715
11/30/2020 10781 22180
6/30/2021 18770 26857
11/30/2021 17491 29093
5/31/2022 13616 23491
11/30/2022 13892 22883
5/31/2023 14771 25712
11/30/2023 18533 28861
5/31/2024 21455 34580
11/30/2024 24565 40326
5/31/2025 23642 39760
11/30/2025 33660 47117

 

Average Annual Return [Table Text Block]

TOTAL RETURNS FOR THE FISCAL PERIOD ENDED NOVEMBER 30, 2025

 

FUND/INDEX ONE YEAR FIVE YEAR TEN YEAR VALUE
Tanaka Growth Fund 37.02% 25.57% 12.90% $33,660
Wilshire 2500 Growth Fund 16.84% 16.26% 16.77% $47,117

 

 

Net Assets $ 31,430,893
Holdings Count | Holdings 25
Advisory Fees Paid, Amount $ 234,409
Investment Company, Portfolio Turnover 23.35%
Additional Fund Statistics [Text Block]

Fund statistics

 

  PORTFOLIO PORTFOLIO ADVISORY FEES
NET ASSETS: HOLDINGS: TURNOVER: PAID BY FUND:
$31,430,893 25 23.35% $234,409

 

Holdings [Text Block]

 

 

Tanaka Pie Chart  
Cash Equivalent 9.12%
Communication Services 1.56%
Consumer Discretionary 1.99%
Consumer Staples 2.25%
Energy 8.75%
Financials 9.90%
Health Care 29.12%
Industrials 7.95%
Info. Technology 20.94%
Materials 8.42%

 

Largest Holdings [Text Block]

Ttop ten holdings (% OF Net ASsets)

 

1. Corcept Therapeutics, Inc. 13.20%
2. Nuvation Bio, Inc. 10.73%
3. Huntington Conservative Deposit Account 9.13%
4. NVIDIA Corp. 7.86%
5. United States Antimony Corp. 6.32%
6. Symbotic Inc. Class A 6.00%
7. Apple, Inc. 5.82%
8. NexGen Energy Ltd. 5.41%
9. Catalyst Pharmaceuticals, Inc. 3.92%
10. Applied Materials, Inc. 3.11%
  Total % of Net Assets 71.50%

 

Material Fund Change [Text Block]

HOW HAS THE FUND CHANGED

 

The Fund has not had any material changes during the year ended November 30, 2025.

Updated Prospectus Phone Number 1-877-4-TANAKA
Updated Prospectus Email Address https://tanaka.com/tanaka-growth-fund